PTCT News
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase ProgramPR NewswireWARREN, N.J., Nov. 3, 2026 WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today...
PR Newswire
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase ProgramPR NewswireWARREN, N.J., Nov. 3, 2026 WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today...
PR Newswire
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireWARREN, N.J., Nov. 2, 2026 WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at...
PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireWARREN, N.J., Oct. 30, 2026 WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced...
PR Newswire
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsPR NewswireWARREN, N.J., Oct. 29, 2026 Strong Q3 2026 performance with total revenue of $358 million, including $276...
PR Newswire
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PR NewswireWARREN, N.J., Oct. 15, 2026WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ...
PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireWARREN, N.J., Sept. 25, 2026 WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced...
PR Newswire